Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.
Dimopoulos MA et al. Leukemia. 2014 Feb 5. doi: 10.1038/leu.2014.60. [Epub ahead of print].
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma.
Engelhardt M et al. Haematologica. 2014 Feb;99(2):232-42. doi: 10.3324/haematol.2013.099358.
The current status of minimal residual disease assessment in myeloma.
Kumar SK et al. Leukemia. 2014 Feb;28(2):239-40. doi: 10.1038/leu.2013.306.
Proteasome inhibitors in progressive renal diseases.
Coppo R. Nephrol Dial Transplant. 2014 Feb;29 Suppl 1:i25-i30. doi: 10.1093/ndt/gft271.
Cellular therapies.
Gottlieb D. Pathology. 2014 Feb;46 Suppl 1:S31. doi: 10.1097/01.PAT.0000443470.87883.27.
Bortezomib and lenalidomide as front-line therapy for multiple myeloma.
Rosiñol L et al. Leuk Lymphoma. 2014 Feb 21. [Epub ahead of print].
Evaluation of mortality among marines and navy personnel exposed to contaminated drinking water at USMC base camp Lejeune: a retrospective cohort study.
Bove FJ et al. Environ Health. 2014 Feb 19;13(1):10. [Epub ahead of print].
Harvesting autologous stem cells from a patient with red blood cell abnormalities of β-thalassemia intermedia.
Sanford K et al. Transfusion. 2014 Feb 17. doi: 10.1111/trf.12579. [Epub ahead of print].
Variation in promptness of presentation among 10,297 patients subsequently diagnosed with one of 18 cancers: Evidence from a national audit of cancer diagnosis in primary care.
Keeble S et al. Int J Cancer. 2014 Feb 11. doi: 10.1002/ijc.28763. [Epub ahead of print].
Multiple myeloma. Diagnosis and treatment.
[No authors listed]. Anticancer Res. 2014 Feb;34(2):1066.
Cancer incidence among firefighters: 45 years of follow-up in five Nordic countries.
Pukkala E et al. Occup Environ Med. 2014 Feb 6. doi: 10.1136/oemed-2013-101803. [Epub ahead of print].
A Catalyst for Change: The European Cancer Patient’s Bill of Rights.
Lawler M et al. Oncologist. 2014 Feb 3. [Epub ahead of print].
Response evaluation and monitoring of multiple myeloma.
Fernández de Larrea C et al. Expert Rev Hematol. 2014 Feb;7(1):33-42. doi: 10.1586/17474086.2014.876899.
The comprehensive clinical management of multiple myeloma and related-plasma cell disorders.
Richardson PG et al. Expert Rev Hematol. 2014 Feb;7(1):1-3. doi: 10.1586/17474086.2014.882763.
Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP et al. Expert Rev Hematol. 2014 Feb;7(1):97-111. doi: 10.1586/17474086.2014.882764. Epub 2014 Jan 29.
The emerging role of consolidation and maintenance therapy for transplant-eligible multiple myeloma patients.
McCarthy PL et al. Expert Rev Hematol. 2014 Feb;7(1):55-66. doi: 10.1586/17474086.2014.878645. Epub 2014 Jan 29.
Allogeneic transplantation in multiple myeloma.
Gahrton G et al. Expert Rev Hematol. 2014 Feb;7(1):79-90. doi: 10.1586/17474086.2014.857270